Replies to post #195218 on Biotech Values

[DewDiligence]

EGRX—I'm worried about the Bendamustine 50ml (Rapid) even though Teva settled all the patent litigation with [EGRX], but Par or Impax may try to do something.

You don’t need to worry, IMO. Although there are multiple paragraph-IV challenges against Teva’s three CoM patents on Treanda (8445524, 8791270, and [for the liquid formulation] 8344006), even if one or more P-IV challengers prevail against all of these patents, they would merely be able to launch a generic version of regular (lyophilized or liquid) Treanda, not the rapid-infusion product that Teva licensed from EGRX.